ReviewOncoimmunology
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Review in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cell surface protein-protein interaction profiling for biological network analysis and novel target discovery.Life medicine · 2024Review
- Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.Nature cancer · 2024Article
- CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.Theranostics · 2022Article
- Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment.World journal of surgical oncology · 2021Article
- Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients.Frontiers in immunology · 2021Article
- Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Immunotherapies in ovarian cancer.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020Article
- Lifting the innate immune barriers to antitumor immunity.Journal for immunotherapy of cancer · 2020Review
- Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy.Immune network · 2020Review
- Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.International journal of cancer · 2019Article
- The Evolving Role of CD8International journal of molecular sciences · 2019Review
- Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.Journal for immunotherapy of cancer · 2019Review
- Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.Frontiers in immunology · 2019Article
- Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.International review of cell and molecular biology · 2019Review
- RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.Journal of neuro-oncology · 2019Article
- Next generation of immune checkpoint therapy in cancer: new developments and challenges.Journal of hematology & oncology · 2018Review
- Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.Frontiers in immunology · 2018Review
- Breast Cancer Immunotherapy: An Update.Breast cancer : basic and clinical research · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.